Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Stem Cell Procurement

Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma

Bone Marrow Transplantation volume 36, pages 951–954 (2005)Cite this article

Summary:

From 2000 to 2004, 152 patients with multiple myeloma aged ⩽65 years, enrolled in high-dose programs, were treated with two schedules of DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin): 106 patients (group I) were mobilized with the infusional version of DCEP (infusional-DCEP), and 46 patients (group II) with a shorter version (DCEP-short). The median number of CD34+ cells collected was similar in the two groups as was the percentage of patients yielding ⩾4 × 106 cells/kg. The proportion of patients in whom mobilization failed was similar in the two groups. The incidence of WHO grade III neutropenia was higher in group II, although the difference was not statistically significant; the percentage of patients requiring hospitalization for severe infections was similar in the two groups. The incidence of WHO grade IV thrombocytopenia did not differ between the two groups. The response rate was 72% in group I and 80% in group II with similar percentages of patients achieving good responses. DCEP-short is a good mobilizing regimen, sharing the same characteristics as infusional-DCEP: high mobilizing efficacy, low toxicity and good antitumor activity. This new schedule of DCEP does, however, allow complete outpatient management and so could be advantageously included in any high-dose therapy program.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroup francais du Myelome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  2. Child J, Morgan G, Davies F et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  PubMed  Google Scholar 

  3. Moreau P, Facon T, Attal M et al. Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroup Francophone du Myelome 9052 randomized trial. Blood 2002; 99: 731–735.

    Article  CAS  PubMed  Google Scholar 

  4. Barlogie B, Jagannath S, Vesole D et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89: 789–793.

    CAS  PubMed  Google Scholar 

  5. Blade J . Transplantation of multiple myeloma: who, when, how often? Blood 2003; 102: 3469–3477.

    Article  CAS  PubMed  Google Scholar 

  6. Barlogie B, Shaugnessy J, Tricot G et al. Treatment of multiple myeloma. Blood 2004; 103: 20–32.

    Article  CAS  PubMed  Google Scholar 

  7. Attal M, Harousseau JL, Facon T et al. A prospective randomized trial of single vs double autologous stem cell transplantation in multiple myeloma. N Engl J Med 2003; 349: 2495–2502.

    Article  CAS  PubMed  Google Scholar 

  8. To LB, Roberts MM, Haylock DN et al. Comparison of haematological recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277–284.

    CAS  PubMed  Google Scholar 

  9. Goldschmidt H, Hegenbart U, Haas R et al. Mobilization of peripheral blood progenitor cells with high-dose cyclophosphamide (4 or 7 g/m2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 691–697.

    CAS  PubMed  Google Scholar 

  10. Kotasek D, Sheperd KM, Sage RE et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11–17.

    CAS  PubMed  Google Scholar 

  11. Alegre A, Tomas JF, Martinez-Chamorro C et al. Comparison of peripheral blood progenitor cell mobilization in patients with multiple myeloma: high dose cyclophosphamide plus GM-CSF vs G-CSF alone. Bone Marrow Transplant 1997; 20: 211–217.

    Article  CAS  PubMed  Google Scholar 

  12. Cook G, Marinaki P, Farrel E et al. Peripheral blood progenitor cell mobilization in patients with multiple myeloma following oral idarubicin and dexamethasone (Z-Dex) induction therapy. Leukemia 1997; 11 (Suppl. 5): 35–40.

    Google Scholar 

  13. Stewart DA, Guo D, Morris D et al. Superior autologous blood stem cell mobilization from dose-intensive cyclophosphamide, etoposide, cisplatin plus G-CSF than from less intensive chemotherapy regimens. Bone Marrow Transplant 1999; 23: 111–117.

    Article  CAS  PubMed  Google Scholar 

  14. Pavone V, Gaudio F, Guarini A et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 285–290.

    Article  CAS  PubMed  Google Scholar 

  15. Hovenga S, de Wolf JT, Guikema JE et al. Autologous stem cell transplantation in multiple myeloma after VAD and EDAP courses: high incidence of oligoclonal serum Igs post transplantation. Bone Marrow Transplant 2000; 25: 723–728.

    Article  CAS  PubMed  Google Scholar 

  16. Desikan KR, Jagannath S, Siegel D et al. Dexamethasone, cyclophosphamide, etoposide and cis-platinum (DCEP), an effective regimen for relapse after high-dose chemotherapy and autologous transplantation. Blood 1996; 88 (Suppl. 1): 2331a.

    Google Scholar 

  17. Desikan R, Munshi N, Zangari M et al. DCEP consolidation chemotherapy after 2 cycles of melphalan-based high-dose therapy. Blood 1999; 94 (Suppl. 1): 1411a.

    Google Scholar 

  18. Lazzarino M, Corso A, Barbarano L et al. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant 2001; 28: 835–839.

    Article  CAS  PubMed  Google Scholar 

  19. Corso A, Arcaini L, Caberlon S et al. A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma. Haematologica 2002; 87: 1041–1045.

    CAS  PubMed  Google Scholar 

  20. Corso A, Barbarano L, Zappasodi P et al. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma. Haematologica 2004; 89: 1124–1127.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Istituto Scientifico Policlinico San Matteo, University of Pavia, Pavia, Italy

    A Corso, S Mangiacavalli, C Castagnola, P Zappasodi, C Astori, M Bonfichi, M Varettoni, C Rusconi, D Troletti, C Pascutto & M Lazzarino

  2. Division of Hematology, Ospedale Niguarda, Milano, Italy

    A Nosari, A M Cafro & E Morra

Authors
  1. A Corso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Mangiacavalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Nosari
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Castagnola
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. P Zappasodi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A M Cafro
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C Astori
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M Bonfichi
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M Varettoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. C Rusconi
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. D Troletti
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. C Pascutto
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. E Morra
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M Lazzarino
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

on behalf of the HOST group

Corresponding author

Correspondence to A Corso.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Corso, A., Mangiacavalli, S., Nosari, A. et al. Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma. Bone Marrow Transplant 36, 951–954 (2005). https://doi.org/10.1038/sj.bmt.1705166

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705166

Keywords

Search

Advanced search

Quick links